Expertise in
1
conditions

Maria Passhak

Haifa, HA, IL 
Expertise in
1
conditions
Haifa, HA, IL 

Overview

Maria Passhak practices practicing medicine in Haifa, Israel.

Ms. Passhak is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Hypersplenism, Heart Tumor, Liposarcoma, and Embolectomy.

She is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Haifa, HA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
View 1 Less Clinical Trial

8 Total Publications

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2025

Frequently Asked Questions about Maria Passhak

Is Maria Passhak a top-rated expert for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)?

MediFind is an objective health platform that identifies experts based on real-world data. Maria Passhak is classified as an Advanced expert for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Maria Passhak participate in research or clinical trials?

Yes. Maria Passhak has published 8 articles and abstracts on conditions like Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). You can view a list of Maria Passhak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Passhak's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile